Dr Nigel Spry

Honorary Associate
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +89 3464900
Fax +89 3464902

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Denham, J., Steigler, A., Tai, K., Joseph, D., Matthews, J., Atkinson, C., Spry, N., Turner, S., North, J., Christie, D., et al (2013). Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiotherapy and Oncology, 107(2), 123-128. [More Information]
  • Ng, E., Woo, H., Turner, S., Leong, E., Jackson, M., Spry, N. (2012). The Influence of Testosterone Suppression and Recovery on Sexual Function in Men With Prostate Cancer: Observations From a Prospective Study in Men Undergoing Intermittent Androgen Suppression. The Journal of Urology, 187(6), 2162-2167. [More Information]
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N., et al (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology, 12(5), 451-459. [More Information]
  • Halkett, G., Merchant, S., Jiwa, M., Short (nee Rybovic), M., Arnet, H., Richardson, S., Kearvell, R., Carson, S., Spry, N., Taylor, M., et al (2010). Effective Communication and Information Provision in Radiotherapy - The Role of Radiation Therapists. Journal of Radiotherapy in Practice, 9(1), 3-16. [More Information]
  • van Ufford-Mannesse, P., Spry, N., Byth Wilson, K., Berry, M., Hayden, L., Korbel, E., Woo, H., Gurney, H. (2005). Changes of bodyweight and lipids during intermittent maximum androgen blockade (IMAB) in the treatment of advanced prostate cancer. Journal of Clinical Oncology, 23(16S (June 1 Supplement)), 418S-418S.
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al (2005). Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology, 6(11), 841-850. [More Information]
  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality following stronutium-89 therapy for mestatic prostate cancer. British Journal of Cancer, 84 (3), 297-302.

2013

  • Denham, J., Steigler, A., Tai, K., Joseph, D., Matthews, J., Atkinson, C., Spry, N., Turner, S., North, J., Christie, D., et al (2013). Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer. Radiotherapy and Oncology, 107(2), 123-128. [More Information]

2012

  • Ng, E., Woo, H., Turner, S., Leong, E., Jackson, M., Spry, N. (2012). The Influence of Testosterone Suppression and Recovery on Sexual Function in Men With Prostate Cancer: Observations From a Prospective Study in Men Undergoing Intermittent Androgen Suppression. The Journal of Urology, 187(6), 2162-2167. [More Information]

2011

  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N., et al (2011). Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology, 12(5), 451-459. [More Information]

2010

  • Halkett, G., Merchant, S., Jiwa, M., Short (nee Rybovic), M., Arnet, H., Richardson, S., Kearvell, R., Carson, S., Spry, N., Taylor, M., et al (2010). Effective Communication and Information Provision in Radiotherapy - The Role of Radiation Therapists. Journal of Radiotherapy in Practice, 9(1), 3-16. [More Information]

2005

  • van Ufford-Mannesse, P., Spry, N., Byth Wilson, K., Berry, M., Hayden, L., Korbel, E., Woo, H., Gurney, H. (2005). Changes of bodyweight and lipids during intermittent maximum androgen blockade (IMAB) in the treatment of advanced prostate cancer. Journal of Clinical Oncology, 23(16S (June 1 Supplement)), 418S-418S.
  • Denham, J., Steigler, A., Lamb, D., Joseph, D., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C., North, J., et al (2005). Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. The Lancet Oncology, 6(11), 841-850. [More Information]

2001

  • Turner, S., Gruenewald, S., Spry, N., Gebski, V. (2001). Less pain does equal better quality following stronutium-89 therapy for mestatic prostate cancer. British Journal of Cancer, 84 (3), 297-302.

To update your profile click here. For support on your academic profile contact .